Get the Stockscreener App
3.08
10.83%
0.31
After Hours:
3.15
0.07
+2.27%
Adc Therapeutics Sa stock is traded at $3.08, with a volume of 881.72K.
It is up +10.83% in the last 24 hours and up +114.69% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$2.77
Open:
$2.75
24h Volume:
881.72K
Relative Volume:
2.08
Market Cap:
$305.47M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-1.0441
EPS:
-2.95
Net Cash Flow:
$-121.90M
1W Performance:
+26.34%
1M Performance:
+114.69%
6M Performance:
+26.86%
1Y Performance:
-10.76%
1-Day Range:
$2.57
$3.11
1-Week Range:
$2.25
$3.05
52-Week Range:
$1.05
$4.13
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.08 | 221.17M | 69.56M | -240.05M | -121.90M | -2.95 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
Astellas and Evopoint sign ADC licensing deal - Pharmaceutical Technology
Woodline Partners LP Takes Position in ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
Shareholders Will Likely Find ADC Therapeutics SA's (NYSE:ADCT) CEO Compensation Acceptable - simplywall.st
BNP Paribas Financial Markets Takes $1.43 Million Position in ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
Equities Analysts Set Expectations for ADCT FY2025 Earnings - MarketBeat
Antibody Drug Conjugates Market will reach 11.5 Billion USD by 2032 - newstrail.com
ADC Therapeutics signals data catalysts ahead with ZYNLONTA combinations, aims for regulatory milestones through 2025 - MSN
BNP Paribas Financial Markets Purchases Shares of 716,668 ADC Therapeutics SA (NYSE:ADCT) - Defense World
FY2025 EPS Estimates for ADCT Increased by Cantor Fitzgerald - Defense World
Orbimed Advisors LLC Acquires 1,434,650 Shares of ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update - Nasdaq
Analysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest Results - simplywall.st
Royal Bank of Canada Reaffirms “Outperform” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics patents new anti-NaPi2b conjugates - BioWorld MedTech
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates - MSN
ADC Therapeutics (ADCT) Receives Reiterated Outperform Rating fr - GuruFocus
ADC Therapeutics presents new anti-ASCT2 conjugates - BioWorld MedTech
ADC Therapeutics SA (NYSE:ADCT) Q1 2025 Earnings Call Transcript - MSN
ADC Therapeutics to Present at Upcoming Investor Conferences - GuruFocus
ADCT Reveals Promising LOTIS-7 Trial Data for ZYNLONTA | ADCT St - GuruFocus
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data - Clinical Trials Arena
ADC Therapeutics reports high response in lymphoma trial By Investing.com - Investing.com Canada
ADC Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
ADC Therapeutics stock plunges 36% amid Zynlonta data release - MSN
ADC Therapeutics SA 2025 Q1ResultsEarnings Call Presentation (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics SA reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : ADC Therapeutics SA, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
ADC Therapeutics Reports First Quarter 2025 Financial Results - TradingView
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) - GuruFocus
ADC Therapeutics reports high response in lymphoma trial - Investing.com
ADC Therapeutics SA Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress and the 18th International Conference on Malignant Lymphoma - marketscreener.com
What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings - GuruFocus
Wells Fargo & Company MN Increases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Barclays PLC Purchases 13,756 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 - BioSpace
JPMorgan Chase & Co. Has $74,000 Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday - MarketBeat
ADC Therapeutics (ADCT) to Release Quarterly Earnings on Monday - Defense World
LPL Financial LLC Invests $50,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):